Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β because we believe great analysis should be held accountable.
The Alchemy of Capital: How Vor Biopharma (VOR) Engineered the Ultimate Wall Street Reset
Vor Biopharma executed a reverse split, insider selling, and major capital raises. This crushed the stock price but secured $450M cash, resetting the company for institutional investors.
The Great Biotech Heist: How Smart Money Washed Retail out of VOR Biopharma
Smart money orchestrated a VOR Biopharma sell-off, then bought back shares at a 60% discount via a PIPE, recapitalizing the company. Retail was washed out.
Vor Biopharma ($VOR): Putting Every Chip on Telitacicept
Vor Biopharma (NASDAQ: VOR) pivoted from oncology to autoimmunity in June 2025 after near-bankruptcy. The company secured exclusive global rights (excluding China) to RemeGen's Phase 3 drug telitacicept and raised $175 million through a PIPE financing. Post-transaction, VOR focuses solely on advancing telitacicept for generalized myasthenia gravis (gMG), leveraging its strong China Phase 3 data. New CEO Dr. Jean-Paul Kress leads execution. Key risks include massive dilution from 700M+ new warrants, a cash runway extending only to late 2026/early 2027 ahead of pivotal 2027 data, and operational constraints with 8 remaining employees. Prior oncology assets (trem-cel, VCAR33) were discontinued.